Company Overview and News

0
Tata Coffee Limited - Updates

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

0
Tata Coffee Limited - Shareholders meeting

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

0
Tata Coffee Limited - Updates

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

4
Tata Global Beverages Q4 profit up 40% at Rs71.56 crore

2018-05-11 livemint
Mumbai: Tata Global Beverages on Friday reported a 39.98% year-on-year rise in consolidated net profit to Rs71.56 crore for the March quarter, led by growth in the firm’s branded business.
532301 TGBL 500800 TATACOFFEE TGBA TTAZF TATAGLOBAL TTAEY

0
Tata Coffee stock slips 7% as Q4 net profit declines 62% YoY

2018-05-08 moneycontrol
Share price of Tata Coffee slipped more than 7 percent intraday Tuesday as company posted weak numbers for the quarter ended March 2018.
532301 TATACOFFEE

0
Tata Coffee Limited - Press Release

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

0
Tata Coffee Limited - Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

0
Tata Coffee Limited - Financial Result Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

0
Tata Coffee Limited - Dividend

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

11
ICICI Bank, Tata Chem, Tata Coffee results

2018-05-04 thehindubusinessline
Saturday-Monday will see close to two dozen companies announcing their quarterly and full-year results for FY 2018. These are Avenue Supermarts, Balaxi Ventures, DIC India, JP Power and Jayant Agro (on Saturday); Intellect Design Arena (Sunday); and Filatex, Firstsource, Hinduja Ventures, ICICI Bank, INOX Leisure, Pfizer, Rane Holdings, Software Group, Shalby, Tata Chemicals, Tata Coffee, Tata Investment, Trident, Tube Investments, Vijaya Bank and Zee Learn (on Monday).
DICIND ZEELEARN TATACOFFEE IBN 532706 TTQQY INOXLEISUR 533287 538835 TATACHEM 532401 VIJAYABANK 532301 HINDUJAVEN ICICIBANK RANEHOLDIN TATAINVEST 532174 501301 500189 INTELLECT 505800 500770 500089

0
Tata Coffee Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532301 TATACOFFEE

31
Sensex, Nifty clock gains for 9th consecutive session; investors await corporate earnings

2018-04-17 moneycontrol
Bulls continued to have upper hand at Dalal Street for the ninth consecutive session on Tuesday after normal monsoon forecast for June-September period, as investors await corporate earnings. Positive global cues also boosted sentiment.
500325 533150 TATACOFFEE UBL RELIANCE RJL 533155 JUBLFOOD 532832 532215 532478 532301 534756 TARAJEWELS AXISBANK RIGD JBLWY 500850 HDFCBANK KAMATHOTEL 500570 INDHOTEL 526668 TATAMOTORS 503100 RLNIY AXB PHOENIXLTD IBN UBHOLDINGS 532505 532923 UNBWY 532843 AXBKY AXBA ICICIBANK GODREJPROP FORTIS HDB 532174 500180 534809 PCJEWELLER UCOBANK 507458 IBREALEST TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...